Integer Stock Slides as CDMO Unveils O-PTFE Tech and Implements eMaint

Introduction

INTEGER HOLDINGS CORPORATION (NYSE: ITGR; ticker ITGR) is a publicly traded medical device contract development and manufacturing organization headquartered in Plano, Texas. As of October 23, 2025, its share price stood at $70.99 on the New York Stock Exchange, reflecting a 34.94% decline year-to-date, with a trading volume of 2,479,437 shares.

Corporate Structure

Founded to serve the cardiac rhythm management, neuromodulation, and cardiovascular markets, Integer operates under well-known brands including Greatbatch Medical®, Lake Region Medical®, and Electrochem®. According to LinkedIn, the company employs over 10,001 associates worldwide. Its manufacturing and R&D capabilities encompass design transfer, prototyping, process development, regulatory oversight, and quality assurance, positioning Integer as one of the largest contract development and manufacturing organizations (CDMOs) in the medical appliances and equipment sector.

Medical Devices by Daniel Frank

Recent Developments and News

• On October 23, 2025, Integer filed a Current Report on Form 8-K (Items 2.02, 7.01, and 9.01) disclosing updates regarding its financial condition and material exhibits.
• On July 24, 2025, the company submitted its Quarterly Report on Form 10-Q for the period ended June 27, 2025, covering key metrics such as revenue trends, operating income, net income, earnings per share, and cash flow.
• In September 2024, after implementing eMaint software across three plants on two continents, Integer achieved a 99.2% work order completion rate and reduced inventory costs through centralized sharing of parts.
• In October 2025, Integer sites worldwide participated in SAFE-Together Day to reinforce workplace safety protocols.
• In the same month, the company showcased VSi Parylene and Precision Coating offerings at MD&M Midwest in Minneapolis.
• During October 2025, Integer introduced its Optimized PTFE Liner Technology (O-PTFE), which reportedly offers a 30% improvement in durability and lubricity for neurovascular catheter applications.

Financial and Strategic Analysis

The decline in Integer’s share price as of October 23, 2025, reflects broader market volatility and sector-specific pressures, including supply chain constraints. The July 2025 Form 10-Q provided comparisons in revenue, margins, and cash flow, along with insights into cost-control measures and ongoing investments in research and development. The implementation of eMaint indicates a focus on operational efficiency and reducing unplanned downtime. The launch of O-PTFE technology illustrates ongoing investment in materials and product differentiation.

Market Position and Industry Context

Integer operates in a competitive environment among other medical device outsourcing manufacturers and contract development organizations. Key end markets—cardiac rhythm management, neuromodulation, and vascular devices—are influenced by FDA regulations and changing clinical needs. Integer’s scale, global presence, and portfolio of proprietary processes enhance its capacity to serve original equipment manufacturer (OEM) partners. Ongoing challenges include navigating regulatory approvals, managing supplier networks, and sustaining research and development pipelines aligned with clinical innovation.

tl;dr

• As of October 23, 2025, ITGR shares traded at $70.99, down 34.94% YTD, with 2.48 million shares exchanged on the NYSE.
• An 8-K filing on October 23, 2025, and the July 24, 2025 10-Q report provided updates on financial conditions and operational performance.
• The September 2024 implementation of eMaint increased work order completion to 99.2% and optimized inventory costs across three plants.
• October 2025 activities included a global SAFE-Together Day, presentations at MD&M Midwest, and the introduction of Optimized PTFE Liner Technology.
• Integer’s near-term focus is on enhancing operational efficiency and technology development to meet market demand and regulatory requirements.